Quality of life should be the primary outcome for disease modifying therapy trials in MS-No. Strijbis E, Koch MW, de Jong BA. Mult Scler 2023;29:1066-1067.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Strijbis E, Koch MW, de Jong BA. Quality of life should be the primary outcome for disease modifying therapy trials in MS-No. Mult Scler 2023;29:1066-1067.
PMID: 37489564